News
12.16.2011
Eutropics diagnostic technology featured in Science Business Exchange
December 15, 2011 * Volume 4 / Number 48 page 7.
Download PDF to read more...
12.12.2011
Eutropics will present a poster at this year’s American Society of Hematology (ASH) meeting in SanDiego.
The poster #3952 titled “Using BH3 profiling as a predictive indicator for myeloma patient response to Bortezomib” describes work done at Eutropics using our proprietary technology to prospectively predict patient response. The work was done in collaboration with the University of Massachusetts Medical School and Dana Farber Cancer institute.
12.01.2011
Maggie Flanagan Leflore, PhD joins Eutropics Business Advisory Board.
Dr. Leflore has extensive experience in life science investment and has held executive positions in pharmaceutical science and business development management, including Astra Zeneca, OSI Pharmaceuticals and Merrel Dow Pharmaceuticals. “Dr. Leflore’s participation provides significant positive input to the development of Eutropic’s core business. We are delighted to have her as a team member and look forward to working with her to build the company to great success.”
10.27.2011
Boston/Cambridge, MA -- A potentially ground breaking approach to predicting cancer patient response to certain treatments is described today in the electronic version of Science Magazine.
The paper describing the technology, called BH3 profiling, is published by Dr. Anthony Letai and colleagues at Boston’s Dana Farber Cancer Institute. The technology assesses the ability of a key part of the cancer cell to respond to chemotherapies. This understanding provides a powerful tool for physicians to gauge ahead of time if a particular cancer treatment will, or will not work in a given patient and can be used to guide the use of existing drugs.
Letai explained, “Our experiments with BH3 profiling demonstrate that understanding of the pretreatment tumor mitochondria can offer valuable predictive information about clinical response. As such, BH3 profiling has the potential to personalize therapy for cancer patients by predicting the quality of a patient’s response to a given treatment.”
This capability is in line with an FDA draft guidance document issued in July of this year calling for companion diagnostic tests for targeted therapies.
The job of commercializing this assay has been assumed by Cambridge, MA based Eutropics Pharmaceuticals, where Dr. Letai serves as chair of the SAB. Eutropics has exclusively licensed the technology from Dana Farber. Currently the test is being developed by the company for use in guiding treatments for multiple myeloma and acute myelogenous leukemia patients.
“Eutropics is uniquely positioned to provide this important test that will help cancer patients receive the appropriate treatments” said Dr. Michael Cardone, CEO of Eutropics Pharmaceuticals. Eutropics’ effort to commercialize the BH3 profiling assay is being done in collaboration with Dana Farber Cancer Institute, University of Massachusetts Medical School, M.D. Anderson Cancer Center, and the National Cancer Institute.
About the company:
Eutropics Pharmaceuticals was founded on research and technology that will enable delivery of personalized medicines to patients suffering from cancer. They seek to displace current treatment paradigms by developing novel therapies tailored to an individual’s cancer profile identified by the proprietary BH3 profiling diagnostic technology. This personalized approach utilizing unique diagnostics and therapeutics should result in more effective treatments and reduce unnecessary suffering. The company is supported by private investors, grants from the NCI, and a loan from the Massachusetts Life Sciences Center.
7.14.2011
Eutropics "Developing Guiding Tools for Selective Targeted Cancer Treatments" article featured in FOCUS, PharmaNet Oncology.
http://www.pharmanet.com/Collateral/Documents/English-US/FOCUS%204th%20issue%20final.pdf
1.3.2011
Eutropics Pharmaceuticals to present at the Personalized Medicine World Conference (PMWC) 2011.
January 18 - 19 in Mountain View, CA.
1.3.2011
Eutropics Pharmaceuticals will occupy new lab and office space in the West Cambridge Science Park.
Our new address is: 767 Concord Avenue, Cambridge, MA.
9.30.2010
Eutropics Pharmaceuticals has signed a phase 1 contract with the National Cancer Institute, Small Business Innovation Research (NCI/SBIR) entitled,” BH3 profiling as a companion diagnostic”.
This first phase of the contract provides funding of $200,000 over 9 months and can be extended into a phase 2. The contract attests to the NCI’s recognition of the utility of the BH3 profiling assay for guiding the use of multiple myeloma therapies. The technology, invented at the Dana Farber Cancer Institute in the lab of Eutropics co-founder and Scientific Advisory Board Chairman Tony Letai, will be developed by Eutropics both as a companion diagnostic for a current multiple myeloma therapies and for Eutropics’ development stage therapeutic compound.
9.17.2010
Eutropics Pharmaceuticals will present at the NCI SBIR Investor Forum at Stanford University on November 9.
In a competitive process Eutropics was selected as one of the most promising NCI SBIR funded emerging companies focused on innovative cancer-related technologies. All of companies who were accepted to the forum were pre-screened by an independent panel of experts from venture capital firms, bio-pharmaceutical, and medical device companies based on strength of research, impact on cancer, product development and market potential. Visit http://sbir.cancer.gov/investorforum/ for program information.
9.9.2010
Eutropics will present as part of the Emerging Company and Innovator's Showcase at the Life Sciences Summit 2010 to be held September 22-23 at SUNY at Stony Brook.
Visit www.lifesciencessummit.org for program information.
8.17.2010
Eutropics Pharmaceuticals Granted Phase 2 SBIR Award
for the Development of Oncology Therapeutic
Today it was announced that Eutropics Pharmaceuticals has received an award from the National Institutes of Health, National Cancer Institute for a Phase 2 Small Business Innovation Research (SBIR) grant to support development of its oncology therapeutic. The grant entitled, “The Development of Small Molecule Inhibitors of Mcl-1 for Cancer Treatment” will be funded for up to two years and up to $1.3M.
“We are grateful to the NCI for recognizing our innovative approach to developing a new therapy for multiple myeloma and other cancers and for supporting our efforts to bring that to the clinic. The award is a strong endorsement of the project and of the Eutropics team. The funding will be critical for the successful development of our Mcl-1 therapeutic and companion diagnostic. We look forward to working with the NCI to deliver a much needed cancer treatment”, said Michael Cardone, CEO of Eutropics.
Eutropics has been working since 2007 to identify novel therapeutic compounds that uniquely target the apoptosis pathway and a novel assay that will guide their use. The earlier stages of this project were supported by a Phase 1 SBIR grant from the NCI/NIH awarded to Eutropics in 2008 as well as by support from the State Of Massachusetts Life Science Center Accelerator Program. The highly successful completion of the Phase 1 study enabled the Phase 2 award reported here.
9.29.2009
Boston lures two life-sciences start-ups.
By Christine McConville, BOSTON HERALD
At a crowded gathering inside a freshly renovated South Boston warehouse, Boston Mayor Thomas M. Menino yesterday introduced the city’s two newest biotech companies.
Ginkgo BioWorks and Eutropics Pharmaceuticals both received assistance from the city’s LifeTech initiative.…………
Eutropics, which develops small molecule therapeutics for the treatment of blood cancer, worked with the city’s LifeTech team to find its 1,500 square-foot office at 609 Albany St.
The start-up, which has five employees, grew out of Harvard Medical School, Dana Farber Cancer Institute and MIT and received $500,000 from the state’s Life Sciences Center.
Eutropics representative Michael Cardone said the city and state assistance was “essential” to bringing his company back into Boston from Woburn.
“A lot of Boston biotechnology companies that start here end up somewhere else because there is a void in incubator financing,” he said.
The city and state support, he said, “encourages them to stay in Boston, near their founding laboratories.”
4.29.2009
Eutropics Pharmaceuticals Receives Massachusetts Life Sciences Center Accelerator Program Award.
It was announced today that Eutropics Pharmaceuticals is one of seven Massachusetts based companies that will receive awards of $500,000 from the Massachusetts Life Sciences Center as part of MLSC’s Accelerator Program.
The Accelerator Program supports and derisks early-stage life sciences companies that are vetted by a Scientific Advisory Board and a Board of Directors. This program is part of the Massachusetts Life Sciences Act. Eutropics Pharmaceuticals was selected as an award recipient after a competitive application process.
"We are very excited to have been selected to receive this award, which will enable the continued growth of Eutropics unique oncology therapeutic and diagnostic programs. This money will have immediate impact on the development of the company and long term benefit to the community as the company grows. The significance of the Accelerator Program in effecting growth of early stage companies like Eutropics cannot be overstated“, said Michael Cardone, CEO of Eutropics.
6.16.2008
Eutropics Pharmaceuticals Granted SBIR Award for the Development of Oncology Theranostic Program.
Eutropics Pharmaceuticals announced today that it has been awarded a Small Business Innovation Research (SBIR) award to support development of its oncology therapeutic and companion diagnostic technology. The National Institutes of Health, National Cancer Institute awarded the phase 1 grant entitled, “The Development of Small Molecule Inhibitors of Mcl-1 for Cancer Treatment”. The funding from this grant will be used to develop an early stage oncology therapeutic utilizing two novel technologies; a novel computational pharmacology approach, and a proprietary screening/diagnostic assay. This SBIR funding fills a void in the early stage funding of innovative approaches to solving unmet medical needs and will help Eutropics establish a value position for further funding.
|
